Delgocitinib cream

DRUG11 trials

Sponsors

Leo Pharma A/S, LEO Pharma, Aalborg University

Conditions

Atopic DermatitisChronic Hand EczemaDiscoid Lupus ErythematosusFrontal Fibrosing AlopeciaHealthy VolunteersItchinessMild to severe palmoplantar pustulosisPalmoplantar Pustulosis

Phase 1

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

CompletedNCT04361136

LEO PharmaHealthy Volunteers

Start: 2020-04-23End: 2020-05-30Updated: 2025-02-24

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

CompletedNCT04807751

LEO PharmaHealthy Volunteers

Start: 2021-03-25End: 2021-07-30Updated: 2025-02-24

Phase 2

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

CompletedNCT03683719

LEO PharmaChronic Hand Eczema

Start: 2018-11-28End: 2020-04-20Updated: 2025-03-12

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

CompletedNCT03725722

LEO PharmaAtopic Dermatitis

Start: 2018-12-28End: 2020-05-19Updated: 2025-03-12

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

TerminatedNCT03958955

LEO PharmaDiscoid Lupus Erythematosus

Start: 2019-07-09End: 2020-04-30Updated: 2025-03-06

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

CompletedNCT05332366

LEO PharmaFrontal Fibrosing Alopecia

Start: 2022-04-19End: 2023-05-22Updated: 2025-03-06

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

RecruitingNCT07013201

LEO PharmaPalmoplantar Pustulosis

Start: 2025-09-11End: 2026-12-14Target: 135Updated: 2026-03-16

A proof-of-concept phase 2a, double-blind, 2-arm trial to investigate efficacy and safety of twice daily delgocitinib cream 20 mg/g compared with cream vehicle during a 16-week treatment period in adult subjects with mild to severe palmoplantar pustulosis

RecruitingCTIS2024-518856-21-00

Leo Pharma A/SMild to severe palmoplantar pustulosis

Start: 2025-08-28Target: 70Updated: 2025-12-03

Phase 3

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema

CompletedNCT04871711

LEO PharmaChronic Hand Eczema

Start: 2021-05-10End: 2022-10-31Updated: 2025-04-08

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

CompletedNCT04872101

LEO PharmaChronic Hand Eczema

Start: 2021-05-25End: 2023-01-06Updated: 2025-04-08

Unknown Phase

The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch

Not yet recruitingNCT07203274

Aalborg UniversityItchiness

Start: 2025-12-01End: 2026-12-31Target: 30Updated: 2025-11-21

Related Papers

Editorial: Exploring innovative therapies for rare inflammatory skin diseases

Frontiers in Medicine2026-03-19

Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.

2026-03-03

Delgocitinib Cream Reduces Itch and Pain in Moderate to Severe Chronic Hand Eczema: Phase 3 DELTA 1 and 2 Pooled Analyses.

2025-12-24

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.

2025-11-15

Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia.

2025-10-141 citations

Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream

Dermatology and Therapy2025-04-05

Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS)

Dermatology and Therapy2024-10-215 citations

653 - Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and -2 trials

British Journal of Dermatology2024-08-016 citations

655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial

British Journal of Dermatology2024-08-015 citations

654 - Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and -2 trials

British Journal of Dermatology2024-08-013 citations

656 - Systemic exposure and safety profile of delgocitinib cream in adults with moderate to severe chronic hand eczema in the phase 3 DELTA-2 trial

British Journal of Dermatology2024-08-011 citations

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.

2024-07-1841 citations

Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity

Archives of Dermatological Research2024-03-2016 citations

Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD).

2024-03-157 citations

Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase <scp>IIb</scp> randomized clinical trial

Contact Dermatitis2023-04-1024 citations